Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Program
On WRAL Monday at 6: Known carcinogens hiding in your childâs classroom? WRAL Investigates why some local schools are refusing to take action
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Editas Medicine
(NQ:
EDIT
)
3.890
+0.020 (+0.52%)
Streaming Delayed Price
Updated: 3:39 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Editas Medicine
< Previous
1
2
3
4
5
6
7
8
9
Next >
Boot Barn To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday
August 08, 2024
Via
Benzinga
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
July 17, 2024
Explore gene-editing stocks with potential to become multibaggers as the industry advances in treating genetic disorders.
Via
InvestorPlace
3 Profitable CRISPR Stocks Earning Analysts’ Praise
July 09, 2024
Revolutionary gene-editing technologies provide promise for investors seeking the most profitable CRISPR stocks today and in the future.
Via
InvestorPlace
The 3 Best Gene Editing Stocks to Buy in July 2024
July 08, 2024
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks.
Via
InvestorPlace
Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich
June 26, 2024
Gene editing is a game-changer, creating substantial opportunities for some of the leading gene editing stocks.
Via
InvestorPlace
Unveiling 5 Analyst Insights On Editas Medicine
June 18, 2024
Via
Benzinga
The Analyst Verdict: Editas Medicine In The Eyes Of 4 Experts
May 30, 2024
Via
Benzinga
The Latest Analyst Ratings For Editas Medicine
February 29, 2024
Via
Benzinga
3 Gene Editing Stocks That Could Make Your Grandchildren Rich
June 25, 2024
Explore gene-editing stocks with long-term growth potential, offering innovative solutions to previously untreatable conditions.
Via
InvestorPlace
Overlooked and Undervalued: 3 Stocks With Jaw-Dropping Upside Potential
May 30, 2024
Invest in these undervalued stocks poised for long-term growth as Wall Street shifts focus to broader market gains.
Via
InvestorPlace
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
May 09, 2024
The company has great potential if and when it enters the commercial stage.
Via
The Motley Fool
EDIT Stock Earnings: Editas Medicine Misses EPS, Misses Revenue for Q1 2024
May 08, 2024
EDIT stock results show that Editas Medicine missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.
March 07, 2024
The company now has a chance to get its lead program out the door a bit sooner.
Via
The Motley Fool
1 Beaten-Down Stock With 55% Upside, According to Wall Street
March 04, 2024
The biotech has bounced back some in the past year.
Via
The Motley Fool
Earnings Outlook For Editas Medicine
February 27, 2024
Via
Benzinga
The Latest Analyst Ratings for Editas Medicine
December 12, 2023
Via
Benzinga
Why Editas Medicine Stock Soared as Much as 42% Higher This Week
March 02, 2024
The clinical-stage genome editing company dropped a couple of important announcements for shareholders.
Via
The Motley Fool
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
February 28, 2024
Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.
Via
Benzinga
TG Therapeutics Soars On In-Line Report; Is The Biotech Rally Buoying Shares?
February 28, 2024
The company reported in-line sales for the fourth quarter, but shares soared by double digits.
Via
Investor's Business Daily
Advance Auto Parts Reports Q4 Results, Joins B&G Foods, Vipshop, ADT And Other Big Stocks Moving Higher On Wednesday
February 28, 2024
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Wednesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
2 Under-the-Radar Stocks With Incredible Upside Potential
January 28, 2024
It's also important to consider their downsides.
Via
The Motley Fool
Could Editas Medicine Become the Next CRISPR Therapeutics?
January 21, 2024
The similarities between the pair are striking, but it might not be enough.
Via
The Motley Fool
7 Mighty Healthcare Stocks Changing the Game of Medicine
January 17, 2024
Thanks to the permanent relevance of medical innovations, investors ought to consider looking at these healthcare stocks.
Via
InvestorPlace
Down 88%, Could Editas Medicine Be a Good Investment Now?
January 15, 2024
The past few years have been difficult ones, but shares of the gene editor are far more attractive now that a CRISPR medicine has passed regulatory hurdles.
Via
The Motley Fool
3 Stocks to Buy in the Booming Field of Gene Editing
January 11, 2024
As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains.
Via
InvestorPlace
Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics
January 08, 2024
These two are at very different stages of the clinical trials process.
Via
The Motley Fool
Editas Just Caught a Break Thanks to Vertex Pharmaceuticals
December 23, 2023
Editas isn't out of the woods yet, but it's better off than before.
Via
The Motley Fool
Bull Of The Day: Crispr Therapeutics
December 11, 2023
CRISPR Therapeutics (CRSP) just made history on Friday with the first FDA-approved gene-editing medicine based on the Nobel Prize-winning discovery that targets disease with the billion-year old...
Via
Talk Markets
1 Promising Stock Down 66% That Could Skyrocket in 2024
December 05, 2023
Financial results aren't what matters most right now for this company.
Via
The Motley Fool
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
December 04, 2023
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.